Axe Compute Sells Cancer Diagnostics Unit to Focus Entirely on Artificial Intelligence Infrastructure
New York, Friday, 18 September 2026.
Axe Compute finalized the sale of its Helomics cancer diagnostics lab to DataMEDS AI, completing its operational pivot into a specialized provider of artificial intelligence cloud computing power.
Transaction Structure and Equity Stake
On September 11, 2026, Axe Compute Inc. (NASDAQ: AGPU) entered into a definitive Stock Purchase Agreement to divest its wholly-owned subsidiary, Helomics Corporation, to DataMEDS AI, Inc. (NASDAQ: MEDS) [3][4]. The transaction was structured as an all-stock deal involving common shares and common share equivalents, granting Axe Compute an equity stake in the acquiring entity [1]. While the agreement was signed earlier in the month, public confirmation and finalization details were disseminated via press release on September 15, 2026, with further coverage extending to September 18, 2026 [1][4]. This divestment represents the final separation of legacy assets from Axe Compute, allowing the company to focus exclusively on its neocloud GPU-as-a-Service infrastructure [1].
Consideration Details and Valuation
Under the terms of the agreement, DataMEDS AI issued 636,328 shares of its common stock to Axe Compute, representing approximately 19.99% of DataMEDS’ outstanding shares prior to the deal closing [2]. In addition to the equity component, the consideration included a $1,363,672 convertible promissory note bearing 7% interest [2]. Some market reports estimated the total purchase value at approximately $1.5 million, implying the equity portion accounts for the remainder of 136328 in value [5]. The promissory note is subject to stockholder approval and contains price protection provisions, with an automatic conversion feature upon approval [2].
Strategic Pivot from Oncology to Neocloud
This transaction marks the culmination of Axe Compute’s strategic transition from its former identity as Predictive Oncology Inc., a name it held until December 2025 [1][4]. Helomics Corporation, based in Pittsburgh, Pennsylvania, was a functional precision medicine oncology platform utilizing AI and real-world tumor data, representing the final operating business from the company’s legacy portfolio [1]. Christopher Miglino, Chief Executive Officer of Axe Compute, stated that the deal is the final chapter of the transformation into a focused, pure-play neocloud GPU-as-a-Service company [1]. By exiting the diagnostics sector, Axe Compute intends to dedicate its entirety of team, capital, and operations to meeting the accelerating demand for AI compute power [1].
Operational Continuity and Investment Logic
Despite the divestment, Axe Compute shareholders retain exposure to the future performance of the Helomics business through their new equity position in DataMEDS AI [1]. Gerald Commissiong, Interim Co-CEO of DataMEDS, noted that the transaction thrusts DataMEDS into the field of oncology, where there is a tremendous need to improve patient outcomes using a data-driven approach [1][4]. DataMEDS AI plans to integrate the Helomics diagnostic platform into its existing AI-driven healthcare ecosystem, ensuring operational continuity for existing oncology clients [1]. This structure allows Axe Compute to become an investor in the technology it helped build while freeing resources for infrastructure scaling [1].
Market Reaction and Financial Context
Following the announcement of the divestment on September 15, 2026, Axe Compute stock experienced heightened trading activity, with volume reaching 5.8 times the daily average [4]. The share price saw an intra-day peak increase of 6.7% before settling with a close gain of 2.23% during the trading session [4]. This market response follows a period of significant capital influx for Axe Compute, which reported receiving over $317 million in customer prepayments for GPU infrastructure on August 18, 2026 [4]. The company had previously signaled its operational pivot in its Q2 2026 earnings report on August 14, 2026, which showed $3.2 million in compute-services revenue [4].
Regulatory Filings and Future Outlook
Axe Compute is required to file a Current Report on Form 8-K with the U.S. Securities and Exchange Commission to provide comprehensive details regarding the transaction terms [3][4]. As of September 18, 2026, the status of the specific 8-K filing detailing the final share counts and ownership percentages remains pending public availability [3]. DataMEDS AI intends to seek stockholder approval for the convertible note within 75 days, upon which the note will automatically convert [2]. Both companies anticipate that this realignment will allow Axe Compute to scale its Axe Compute Access and Axe Compute Build platforms while DataMEDS expands its health-data capabilities [1][4].